High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Issue 12 (December 2014)

• Record Type: Journal Article
• Authors: Laszlo, George S.; Ries, Rhonda E.; Gudgeon, Chelsea J.; Harrington, Kimberly H.; Alonzo, Todd A.; Gerbing, Robert B.; Raimondi, Susana C.; Hirsch, Betsy A.; Gamis, Alan S.; Meshinchi, Soheil; Walter, Roland B.
• Is Part Of: Leukemia & lymphoma. Volume 55:Issue 12(2014:Dec.)
• Page Start: 2817
• Page End: 2821
• Publication Date: 2014-12
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.893305
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Deregulated cytokine signaling is a characteristic feature of acute myeloid leukemia (AML), and expression signatures of cytokines and chemokines have been identified as a significant prognostic factor in this disease. Given this aberrant signaling, we hypothesized that expression of suppressor of cytokine signaling-2 (SOCS2), a negative regulator of cytokine signaling, might be altered in AML and could provide predictive information. Among 188 participants of the Children's Oncology Group AAML03P1 trial, SOCS2 mRNA levels varied &gt; 6000-fold. Higher (&gt; median) SOCS2 expression was associated with inferior overall (60 ± 10% vs. 75 ± 9%, <italic>p</italic> = 0.026) and event-free (44 ± 10% vs. 59 ± 10%, <italic>p</italic> = 0.031) survival. However, these differences were accounted for by higher prevalence of high-risk and lower prevalence of low-risk disease among patients with higher SOCS2 expression, limiting the clinical utility of SOCS2 as a predictive marker. It remains untested whether high SOCS2 expression identifies a subset of leukemias with deregulated cytokine signaling that could be amenable to therapeutic intervention.</p> </abstract>